ARTICLE | Product Development
AZ and Oxford paper spotlights the swerves on the road to pooled vaccine efficacy readout
A dive into AZ and Oxford’s efficacy analysis for AZD1222
December 11, 2020 11:14 PM UTC
The first peer-reviewed paper on pivotal data from a COVID-19 vaccine details the unplanned protocol shifts complicating the pooled efficacy analysis of AstraZeneca and Oxford’s AZD1222.
The Lancet study, published Tuesday, contains the efficacy and safety data for the adenoviral vector vaccine, which AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and University of Oxford have submitted to regulators around the world. ...